Home Experts Corner Fitness & Health Research Article: Stem cell therapy for former N.F.L. Players

Research Article: Stem cell therapy for former N.F.L. Players


Autologous bone marrow concentrate (BMC) for the treatment of Osteoarthritis (O.A) of the Knee, Hip, and Shoulder in former n.f.l. players

 Kenneth A. Pettine1, Richard K. Suzuki2, Mathew B. Murphy2, Kathryn Moncivais2, Meghana Malur2

1  BennuLife Regenerative Institute, USA

2Celling Biosciences, R&D Department, USA

Corresponding author: Meghana Malur, Celling Biosciences, 4719 South Congress Avenue, Austin, Texas, USA. Telephone: 512-968-2553, fax: 512-637-2096

e-mail:[email protected]

Autologous bone marrow concentrate (BMC) for the treatment of Osteoarthritis (O.A) of the Knee, Hip, and Shoulder in former n.f.l. players

  1. Abstract

The use of bone marrow concentrate, (BMC), to treat Osteoarthritis (O.A) is the standard of care in veterinary medicine. There remains a paucity of clinical data on the safety and efficacy of utilizing BMC in humans. Fifty-one former N.F.L. players were injected with BMC for shoulder (n=30), hip (n=11) or knee (n=10) osteoarthritis. All were surgical candidates. At one year follow-up up the average shoulder patient improved 68% in VAS, 64% in QuickDASH and 40% in ASES. The average hip patient improved 70% in VAS, 72% in ODI and 64% in Lower Extremity Functional Scale (LEFS). The average knee patient improved 70% in VAS, 67% in ODI and 62% in LEFS. All improvements were to a p<0.001. There were no complications and no patient was made worse. Only (1/30) shoulder, (1/11) hip and (2/10) knee patients elected to have surgery at minimum 1 year follow-up.

  1. Keywords

Autologous, Regenerative Medicine, Osteoarthritis, Bone Marrow Concentrate, Mesenchymal Stem Cells, National Football League (N.F.L.)

  1. Abbreviations

Bone marrow concentrate (BMC), National Football League (N.F.L.), Osteoarthritis (O.A), Oswestry disability index (ODI), Visual Analog Scale (VAS), Lower Extremity Functional Scale (LEFS), QuickDASH (QD), American Shoulder and Elbow Surgeons (ASES)

  1. Introduction

Osteoarthritis (O.A) affects over 50 million Americans. This includes mostly O.A of the shoulder, hip, and knee. Shoulder osteoarthritis (O.A) has been demonstrated in cadaver and radiographic studies to affect up to 33% of patients over the age of 60 1. Patients with shoulder O.A have pain, crepitus, decreased ability to place their hand at a desired point in space and loss of motion, severely impairing activities of daily living. The nonsurgical treatments for shoulder O.A include the use of analgesics, non-steroidal anti-inflammatory medications, and shoulder exercises to maintain range of motion. The surgical treatment for shoulder O.A is total shoulder arthroplasty 1,2.

The American Academy of Orthopedic Surgeons (AAOS) recommended treatment for O.A of the hip and the knee include the following: weight loss, gentle exercise, and anti-inflammatory medications followed by total hip or knee replacement. The AAOS does not recommend arthroscopic debridement or any Hyaluronic acid products such as Synvisc®, Euflexxa, Orthovisc®, Supartz, or Hyalgan® for treating hip and knee osteoarthritis. Four prospective randomized studies have shown no benefit over placebo at six-month follow-up with these Hyaluronic injections. Despite the fact Hyaluronic acid products have shown no efficacy, the market for these products is several hundred million dollars per year3–8. The reason for this is the huge void between non-operative treatments and the only surgical treatment, total hip, or knee arthroplasty. Last year in the United States, over 1 million total hip and knee replacements were performed with a direct cost of over $30 billion9,10. These numbers are expected to double in the next three years (AAOS.org)9. Every day, 10,000 people in the United States turn 65 and this will continue for the next 14 years (aarp.org) increasing the population that will be in the need of total joint replacements.

Read the entire research paper here.